Novartis Plans to Move Infectious Disease Research Group to the Bay Area
This article was originally published in The Pink Sheet Daily
The company has hired a high-profile professor with a nose for virus sleuthing as its new ID chief, and it will start shifting its 120-member R&D staff from the Boston area next year.
You may also be interested in...
Phase I study combining two of the biotech's drugs reveals liver problems.
In paying $5.1 billion for vaccine maker Chiron, Novartis is pursuing a unique business strategy which recognizes the growing role of governments, both as purchasers and as price-setters. The same strategy assumes, too, that pharma must seek alternative growth sources to branded prescription drugs.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.